Report Ocean has published a new report on the Retinal Vein Occlusion Treatment Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

The new company said it plans to drive development of TH-103 for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema and retinal vein occlusion. The phase I study is ...

KOCHI: 68-year-old Thankamma (name changed) from Ernakulam has been a diabetic patient for 15 years. As she did not manage ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...